Latest Innovation News

Cleo Diagnostics unveils a pioneering blood test for early ovarian cancer detection, boasting superior accuracy to existing methods and targeting a significant U.S. market opportunity.

Brazilian Rare Earths has successfully produced high-purity mixed-rare-earth carbonate and uranium yellowcake from its Monte Alto Project, marking a key milestone in its integrated supply chain ambitions.

Vulcan Energy has extended its conditional debt commitment letter to September 2025, aligning with its revised financing timeline for the Lionheart Project. This move supports ongoing bank discussions and the potential inclusion of significant government funding.

Nanoveu Limited has locked in a $500,000 funding guarantee through an options underwriting agreement, underpinning its push to commercialise cutting-edge semiconductor and 3D visualisation technologies.

Talga Group has cleared the last regulatory hurdle for its Nunasvaara South graphite mine in Sweden, paving the way for production of battery anode materials critical to the green transition.

Lindian Resources has secured a combined $1.65 million cash inflow from the exercise of unlisted options and a government R&D tax refund, strengthening its financial position for advancing the Kangankunde Rare Earths Project.

Telix Pharmaceuticals showcased its global theranostic radiopharmaceutical portfolio, highlighting FDA approvals, clinical progress, and a robust commercial expansion plan at its 2025 Investor Day.

DigitalX Limited's treasury reached a record A$75.9 million in May 2025, propelled by increased Solana holdings and enhanced staking yields. The company’s innovative approach balances Bitcoin’s stability with yield-generating digital assets.

Noxopharm’s Sofra™ technology has received promising external validation from BioRay Pharmaceutical, confirming its targeted anti-inflammatory potential and broad applicability in autoimmune disease therapies.

Johns Lyng Group has received a conditional, non-binding acquisition proposal from Pacific Equity Partners, sparking a potential shift in ownership with key management poised to retain stakes. The company has granted exclusivity for due diligence, setting the stage for a possible binding offer.

PYC Therapeutics has secured Safety Review Committee approval to increase dosing in its clinical trial for a novel treatment targeting Autosomal Dominant Optic Atrophy, a rare blinding genetic disease. This milestone marks a significant step forward in the development of PYC-001, a first-in-class RNA therapy.

Etherstack has landed a $1 million contract to supply digital radio network equipment to the world’s largest iron ore producer in Western Australia, reinforcing its growth in recurring revenues. The company also reports record cash receipts in the first half of 2025, signaling strong momentum.